Actively Recruiting
Evaluating Safety, Reactogenicity, and Immune Response of mRNA-1010 Vaccine in Healthy Children Ages 9 to Under 18
Led by ModernaTX, Inc. · Updated on 2026-10-28
96
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, reactogenicity, and immune response of the mRNA-1010 vaccine in healthy children aged 9 to under 18 years. This is a Phase 1 clinical trial focusing on prevention of seasonal influenza. The study aims to evaluate how the vaccine performs in terms of triggering immune protection and any side effects in this young population. Participants will be randomly assigned to receive either a single low dose or a single full dose of mRNA-1010 vaccine by intramuscular injection on Day 1, or a single dose of an active comparator vaccine called Fluarix Trivalent. The study is blinded and uses a sequential model to escalate doses. The intervention occurs only once on the first day. Participants will be monitored for local and systemic reactions for 7 days after vaccination and for adverse events up to 28 days. Safety follow-up continues for up to one year to detect any serious or medically attended events. Immune response will be measured on Day 29 through antibody tests. The total participation lasts up to 365 days, including safety and immunogenicity assessments.
CONDITIONS
Brief Title
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
Research Team
M
Moderna WeCare Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here